# US 2023/0398090 A1 · Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398090 A1
- Document ID: US20230398090A1
- Status: Published application
- Kind: A1
- Application number: 17/913,086
- Filed: 2021-03-24
- Published: 2023-12-14
- Earliest claimed: 2020-03-27
- Assignees: Beech Tree Labs, Inc.
- Applicants: Beech Tree Labs, Inc.
- Inventors: John McMichael
- Web page: https://patentgrep.com/patent/US20230398090A1

## CPC

- A61K 31/305: Mercury compounds
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of treating a coronavirus infection by administration of ethyl mercury or thiol derivative thereof in an amount effective to treat the coronavirus infection.

## Claims

### Claim 1

A method of treating a coronavirus infection in a subject comprising administering ethyl mercury or thiol derivative thereof to the subject in an amount effective to treat the viral infection.

### Claim 2 (depends on 1)

The method of claim 1, wherein the coronavirus infection is caused by a member selected from the group consisting of SARS-CoV-1 and SARS-CoV-2.

### Claim 3 (depends on 2)

The method of claim 2, wherein the coronavirus infection is caused by SARS-CoV-2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the thiol derivative of ethyl mercury is thimerosal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 6 (depends on 1)

The method of claim 1, wherein treatment results in improvement in one or more biometric measures selected from the group consisting of oxygen saturation, temperature, level of pain, coughing, pulse, sore throat, “COVID toes” respiratory rate, sense of taste and sense of smell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering step comprises a route of administration selected from the group consisting of sublingual and subcutaneous administration.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ethyl mercury or thiol derivative thereof is administered sublingually.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ethyl mercury or thiol derivative is administered at a dosage range of about 0.05 μg to about 500 μg.

### Claim 10 (depends on 8)

The method of claim 8, wherein the ethyl mercury or thiol derivative is administered at a dosage range of about 0.2 μg to about 50 μg.

### Claim 11 (depends on 8)

The method of claim 8, wherein the ethyl mercury or thiol derivative is administered at a dose of about 0.2 μg.

### Claim 12 (depends on 8)

The method of claim 8, wherein the ethyl mercury or thiol derivative is administered in one drop intervals at least three times a day.
